Dr. Adwait G. Mehta, MD

Dr. Mehta practices at The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System.

Dr. Mehta's NPI, 1699023200, was assigned on August 29, 2012. Dr. Mehta graduated from Royal College of Surgeons Ireland in 2011. Dr. Mehta holds Texas license S0020.

Dr. Mehta's primary practice is The University of Texas MD Anderson Cancer Center, at 1515 Holcombe Blvd, Houston, TX 77030.

Dr. Mehta's primary practice is The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System. The medical group on file is Physicians Referral Service.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Mehta practices. Vendor and product names are available with a free account.

Internal medicine is Dr. Mehta's primary specialty in the NPI Registry, under taxonomy code 207R00000X. Dr. Mehta is board certified in internal medicine by the American Board of Internal Medicine. Dmand AI has Dr. Mehta's licenses on file in 3 states: Texas, New Mexico and Massachusetts.

Dmand AI lists gastrointestinal inflammation among the conditions Dr. Mehta treats.

CMS data shows 174 Medicare services from Dr. Mehta across 3 procedure codes in 2024, for 81 Medicare patients. Medicare paid $18,072 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 81 Medicare patients who saw Dr. Mehta in 2024. The largest group is 65 to 74, with 37 patients. 75% of them have high blood pressure, and 73% have high cholesterol. 32% are also on Medicaid. Their average risk score is 2.35, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Mehta's median patient age at 70, with 53% women.

In 2024, Dr. Mehta wrote 27 Medicare Part D claims for 12 patients. 100% of them were for generic drugs. They cover 11 drugs, with $9,315 in total drug cost. In 2018, CMS named 366 claims across 13 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Mehta for performance year 2024, reported as part of a group. Dr. Mehta accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 6 papers to Dr. Mehta, published from 2019 to 2025. 2020 was the busiest year, with 4. Dr. Mehta's most frequent co-authors are Nilesh S. Mathuria, MD, Mark Stephen Pollet, MD and Gabriel Marcelo Aisenberg, MD.

CMS Open Payments shows 18 general payments to Dr. Mehta from 9 drug and device companies from 2016 to 2025. Travel and lodging make up the largest share, 60% of the total. Boston Scientific Corporation paid the most, $1,596.

Dr. Mehta graduated from Royal College of Surgeons Ireland in 2011.

Dr. Mehta is in network with 19 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 12. Check the plan with the practice before a visit.